-

05:38:22 AM

WXXWY Stock News

WXXWY - Wuxi Biologics (Cayman) Inc.

06/01/23 4:49 AM

OTC : WXXWY

WuXi Biologics to Increase Manufacturing Capacity in Germany

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization, today announced that it...

RHEA-AI

very positive

05/22/23 4:30 AM

OTC : WXXWY

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization, today announced that the International Society for Pharmaceutical Engineering has awarded the company a 2023 Facility of the Year Award in the Operations category. WuXi Biologics was recognized for using innovative...

RHEA-AI

very positive

05/16/23 4:00 AM

OTC, Nasdaq : WXXWY, IFRX

partnershipcovid-19

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced the manufacturing partnership with InflaRx for its COVID-19 treatment Gohibic. InflaRx, a clinical-stage biopharmaceutical company headquartered in Jena, Germany developing anti-inflammatory therapeutics...

RHEA-AI

very positive

04/28/23 2:43 AM

OTC : WXXWY

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization, released its 2022 Environmental, Social and Governance Report, which provides a transparent and all-encompassing update on the company's efforts to advance a healthy and sustainable society. "2022 was another record year for WuXi Biologics, with strong...

RHEA-AI

positive

04/17/23 1:43 AM

OTC : WXXWY

WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization and its subsidiary WuXi XDC congratulate their partner DualityBio, a clinical-stage biotech company focusing on the discovery and development of next generation ADC therapeutics for patients with cancer and autoimmune diseases, on entering into exclusive...

RHEA-AI

very positive

03/28/23 7:05 AM

OTC, Nasdaq : WXXWY, FOLD

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, congratulates its strategic partner Amicus Therapeutics on receiving European Commission's approval for Pombiliti™, a long-term enzyme replacement therapy used in combination with miglustat for adults with late-onset Pompe disease.

RHEA-AI

very positive

03/22/23 8:09 AM

OTC : WXXWY

WuXi Biologics Reports Remarkable 2022 Annual Results

WuXi Biologics Inc., a leading global Contract Research, Development and Manufacturing Organization service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended 31 December 2022. Beginning in the second half of 2022, the Group has been in active...

RHEA-AI

very positive

03/08/23 7:30 PM

OTC : WXXWY

WuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conjugate

WuXi XDC, a leading global CRDMO company dedicated to end-to-end bioconjugate services, congratulates its partner, the Experimental Drug Development Centre, Singapore's national drug discovery and development platform hosted by the Agency for Science, Technology and Research, and its collaborators on clearance by the...

RHEA-AI

very positive

01/04/23 7:30 PM

OTC, NYSE : WXXWY, GSK

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms WuXi Biologics will receive an upfront payment

RHEA-AI

very positive

12/15/22 7:44 PM

OTC : WXXWY

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics ( Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S.

RHEA-AI

neutral

1 2 3 4 5 6 Next